.

Olodaterol for the treatment of chronic obstructive pulmonary disease

LAUR Repository

Show simple item record

dc.contributor.author Kabbara, Wissam K.
dc.contributor.author Ramadan, Wijdan H.
dc.contributor.author Abilmona, Rosa M.
dc.date.accessioned 2016-10-03T09:32:32Z
dc.date.available 2016-10-03T09:32:32Z
dc.date.copyright 2016 en_US
dc.identifier.issn 1695-0674 en_US
dc.identifier.uri http://hdl.handle.net/10725/4488
dc.description.abstract Purpose. Published data on the pharmacology, pharmacokinetics, efficacy, and safety of the once-daily, long-acting β2-agonist (LABA) olodaterol are reviewed. Summary. Olodaterol (Striverdi Respimat, Boehringer Ingelheim), a LABA with high selectivity for β2-adrenergic receptors, is indicated for the treatment of chronic obstructive pulmonary disease (COPD); the recommended dose is 5 µg, to be delivered once daily via the Respimat inhaler. In 48- and 6-week Phase III clinical trials of olodaterol evaluating various lung function and symptomatic outcomes in patients with moderate to very severe COPD, olodaterol use was associated with significant improvements in spirometry outcomes, such as postbronchodilator forced expiratory volume in one second (FEV1), as well as dyspnea severity and quality-of-life measures. Other clinical trials demonstrated that olodaterol produced beneficial effects on FEV1 measures throughout the 24-hour dosing interval. A meta-analysis of data from 20 published research reports indicated that olodaterol's efficacy was comparable to that of the once-daily LABA in-dacaterol and that the combination of olodaterol and tiotropium provided improvements in lung function greater than those provided by tiotropium alone. Analysis of pooled data from four long-term trials showed that olodaterol's safety profile was comparable to that of formoterol; the most frequently reported adverse effects associated with olodaterol use were bronchitis, nasopharyngitis, and upper respiratory tract infection. Conclusion. Once-daily olodaterol 5 µg is an effective therapy in improving lung function and symptomatic outcomes in patients with moderate to very severe COPD receiving other maintenance therapy, with a satisfactory safety profile en_US
dc.language.iso en en_US
dc.title Olodaterol for the treatment of chronic obstructive pulmonary disease en_US
dc.type Article en_US
dc.description.version Published en_US
dc.author.school SOP en_US
dc.author.idnumber 200104485 en_US
dc.author.idnumber 199312180 en_US
dc.author.department Pharmacy Practice Department en_US
dc.description.embargo N/A en_US
dc.relation.journal American Journal of Health-System Pharmacy en_US
dc.journal.volume 73 en_US
dc.journal.issue 15 en_US
dc.article.pages 1135-1143 en_US
dc.identifier.doi http://dx.doi.org/10.2146/ajhp150364 en_US
dc.identifier.ctation Ramadan, W. H., Kabbara, W. K., & Abilmona, R. M. (2016). Olodaterol for the treatment of chronic obstructive pulmonary disease. American Journal of Health-System Pharmacy, 73(15). en_US
dc.author.email wissam.kabbara@lau.edu.lb en_US
dc.author.email wramadan@lau.edu.lb en_US
dc.identifier.tou http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php en_US
dc.identifier.url http://web.a.ebscohost.com/ehost/detail/detail?sid=c8392873-75ac-4f48-89de-7027bb84e6d8%40sessionmgr4008&vid=0&hid=4101&bdata=JnNpdGU9ZWhvc3QtbGl2ZQ%3d%3d#AN=117499790&db=a9h en_US
dc.orcid.id https://orcid.org/0000-0002-7310-9192 en_US


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search LAUR


Advanced Search

Browse

My Account